MELD accurately predicts mortality in patients with alcoholic hepatitis

Hepatology

Volumn 41, Issue 2, 2005, Pages 353-358

  Dunn, Winston ^a   Jamil, Laith H ^a   Brown, Larry S ^a   Wiesner, Russell H ^a   Kim, W Ray ^a   Menon, K V Narayanan ^a   Malinchoc, Michael ^a   Kamath, Patrick S ^a   Shah, Vijay ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BILIRUBIN; CREATININE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CREATININE BLOOD LEVEL; DISEASE MODEL; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VALIDATION PROCESS;

ADULT; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; FEMALE; HEPATITIS, ALCOHOLIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 12844276509     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20503     Document Type: Article

References (24)

1. Menon K, Gores G, Shah V. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001;76:1021-1029.
2. Morgan TR. Treatment of alcoholic hepatitis. Semin Liver Dis 1993;13:384-394.
3. Imperiale T, McCullough A. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990;113:299-307.
4. McCullough A, O'Connor J. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998;93:2022-2036.
5. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
6. Morgan T, McClain C. Pentoxifylline and alcoholic hepatitis. Gastroenterology 2000;119:1787-1791.
7. Maddrey W, Boitnott J, Bedine M, Weber FJ, Mezey E, White RJ. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.
8. Carithers RJ, Herlong H, Diehl A, Shaw E, Combes B, Fallon H, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110:685-690.
9. Kulkarni K, Tran T, Medrano M, Yoffe B, Goodgame R. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004;38:453-459.
10. Mathurin P, Mendenhall C, Carithers Jr R, Ramond M, Maddrey W, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:547-548.
11. Mendenhall C, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff L, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984;311:1464-1470.
12. Orrego H, Israel Y, Blake J, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. HEPATOLOGY 1983;3:896-905.
13. Malinchoc M, Kamath P, Gordon F, Peine C, Rank J, ter Borg P. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. HEPATOLOGY 2000;31:864-871.
14. Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001;33:464-470.
15. Wiesner R, McDiarmid S, Kamath P, Edwards E, Malinchoc M, Kremers W, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580.
16. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
17. Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992;326:507-512.
18. DeLong E, DeLong D, Clarke-Pearson D. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.
19. Menon K, Stadheim L, Kamath P, Gores G, Peine C, Shah V. Safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99:255-260.
20. Mathurin P, Abdelnour M, Ramond M, Carbonell N, Fartoux L, Serfaty L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. HEPATOLOGY 2003;38:1363-1369.
21. Kamath P, Kim W. Is the change in MELD score a better indicator of mortality than baseline MELD score? Liver Transpl 2003;9:19-21.
22. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2001;2:2.
23. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903.
24. Williams JJ, Simel D. The rational clinical examination. Does this patient have ascites? How to divine fluid in the abdomen. JAMA 1992;267:2645-2648.